CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
News
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
– Kriya’s therapeutic pipeline addresses a broad range of diseases that collectively affect millions of…
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
– Kriya’s therapeutic pipeline addresses a broad range of diseases that collectively affect millions of…
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead…
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead…
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American:…
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American:…
Oculis Announces to Present at Upcoming August Investor Conferences
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS)…
Oculis Announces to Present at Upcoming August Investor Conferences
ZUG, Switzerland, and BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS)…
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today…
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today…
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…